[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342990-105":59,"doc-detail-342990-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dhodh-inhibition-enhances-the-efficacy-of-immune-checkpoint-blockade-by-increasing-cancer-cell-antigen-presentation","DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation","","Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and pyrimidine-targeting chemotherapy agents underpin treatment for many cancers. Dihydroorotate dehydrogenase (DHODH), an essential enzyme in de novo pyrimidine biosynthesis, can be inhibited using clinically approved inhibitors, yet DHODH drugs show limited single-agent activity in early clinical trials. Mechanistic work reveals that DHODH inhibition increases antigen presentation and MHC class I expression via pyrimidine nucleotide depletion and P-TEFb–mediated RNA polymerase II elongation control. Combination with brequinar and dual checkpoint blockade prolongs mouse survival and supports rational clinical combination strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dhodh-inhibition-enhances-the-efficacy-of-immune-checkpoint-blockade-by-increasing-cancer-cell-antigen-presentation/342990/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dhodh-inhibition-enhances-the-efficacy-of-immune-checkpoint-blockade-by-increasing-cancer-cell-antigen-presentation/342990.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main biological effect of DHODH inhibition described in the document?","Question",{"text":112,"@type":113},"DHODH inhibition increases antigen presentation pathway activity, leading to higher cell-surface MHC class I expression in cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do the authors argue DHODH inhibitors may have limited single-agent activity in clinical trials?",{"text":117,"@type":113},"Despite strong preclinical efficacy, limited single-agent activity in early phase trials motivates exploration of combination strategies and underlying therapeutic vulnerabilities.",{"name":119,"@type":110,"acceptedAnswer":120},"How does brequinar combination therapy influence treatment outcomes?",{"text":121,"@type":113},"Brequinar shows strong single-agent efficacy in an immunocompetent melanoma model, and combining brequinar with dual immune checkpoint blockade significantly prolongs mouse survival compared with either therapy alone.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342990,1790171556,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","RESEARCH ARtICLE  \nDHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation  \n*For correspondence:  \n[pankaj-singh@ouhsc.edu](pankaj-singh@ouhsc.edu)[ ](pankaj-singh@ouhsc.edu)Competing interest: See page 18  \nFunding: See page 18  \nSent for Review  \n03 April 2023  \nPreprint posted  \n05 April 2023  \nReviewed preprint posted  \n23 May 2023  \nReviewed preprint revised  \n05 April 2024  \nVersion of Record published  \n08 July 2024  \nReviewing Editor: Lynne-Marie Postovit, Queen's University, Canada  \n Copyright Mullen et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use andredistribution provided that the original author and source are credited.  \nNicholas J Mullen1, Surendra K Shukla2, Ravi Thakur2, Sai Sundeep Kollala1, Dezhen Wang1, Nina Chaika1, Juan F Santana3, William R Miklavcic1, Drew A LaBreck2, Jayapal Reddy Mallareddy1, David H Price3,  \nAmarnath Natarajan1, Kamiya Mehla2, David B Sykes4,5, Michael A Hollingsworth1, Pankaj K Singh1,2,6*  \n1 Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States; 2 Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, United States; 3 Department of Biochemistry and Molecular Biology, University of Iowa, Iowa City, United States; 4Center for Regenerative Medicine, Massachusetts General Hospital, Boston, United States; 5 Harvard Stem Cell Institute, Cambridge, United States; 6OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, United States  \nAbstract Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and chemotherapy agents targeting pyrimidine metabolism are the backbone of treatment for many cancers. Dihydroorotate dehydrogenase (DHODH) is an essential enzyme in the de novo pyrimidine biosynthesis pathway that can be targeted by clinically approved inhibitors. However, despite robust preclinical anticancer efficacy, DHODH inhibitors have shown limited single-agent activity in phase 1 and 2 clinical trials. Therefore, novel combination therapy strategies are necessary to realize the potential of these drugs. To search for therapeutic vulnerabilities induced by DHODH inhibition, we examined gene expression changes in cancer cells treated with the potent and selective DHODH inhibitor brequinar (BQ) . This revealed that BQ treatment causes upregulation of antigen presentation pathway genes and cell surface MHC class I expression. Mechanistic studies showed that this effect is (1) strictly dependent on pyrimidine nucleotide depletion,(2) independent of canonical antigen presentation pathway transcriptional regulators, and (3) mediated by RNA polymerase II elongation control by positive transcription elongation factor B (P-TEFb) . Furthermore, BQ showed impressive single-agent efficacy in the immunocompetent B16F10 melanoma model, and combination treatment with BQ and dual immune checkpoint blockade (anti-CTLA-4 plus anti-PD-1) significantly prolonged mouse survival compared to either therapy alone. Our results have important implications for the clinical development of DHODH inhibitors and provide a rationale for combination therapy with BQ and immune checkpoint blockade.  \neLife assessment  \nThis important study reports a novel mechanism linking DHODH inhibition and subsequent pyrimidine nucleotide depletion with upregulation of cell surface MHC I in cancer cells. The in vitro mechanistic data are compelling, with rigorous methodology and validation across multiple cell lines. The  \nMullen et al. eLife 2023;12:RP87292. DOI: [https://doi.org/10.7554/eLife.87292](https://doi.org/10.7554/eLife.87292) 1 of 23  \n Research article Cancer Biology | Immunology and Inflammation  \nauthors also provide in vivo evidence for additive effects of DHODH inhibitors and immune checkpoint blocka","cbCaicrn8RYHvPs0","https://ap.wps.com/l/cbCaicrn8RYHvPs0","pdf",7533866,23,"English","# Abstract\n# eLife assessment\n# Introduction\n## Cancer metabolism and immune evasion\n## DHODH as a druggable dependency","[{\"question\":\"What is the main biological effect of DHODH inhibition described in the document?\",\"answer\":\"DHODH inhibition increases antigen presentation pathway activity, leading to higher cell-surface MHC class I expression in cancer cells.\"},{\"question\":\"Why do the authors argue DHODH inhibitors may have limited single-agent activity in clinical trials?\",\"answer\":\"Despite strong preclinical efficacy, limited single-agent activity in early phase trials motivates exploration of combination strategies and underlying therapeutic vulnerabilities.\"},{\"question\":\"How does brequinar combination therapy influence treatment outcomes?\",\"answer\":\"Brequinar shows strong single-agent efficacy in an immunocompetent melanoma model, and combining brequinar with dual immune checkpoint blockade significantly prolongs mouse survival compared with either therapy alone.\"}]","DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation | PDF",1790049288,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e4f78c242ab79656644ea4f49249931.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47abd0e5d506c46a03dd53dd716f5abf.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b4c4d5f87969e2c742dd841f3b36f27.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67745ec76c57da5f798bc8dfe43e90e4.webp",980,1268]